Back
Compare AU
Compare CURE vs. LNYN
Compare shares and ETFs on the ASX that you can trade on Pearler.
Overview
When it comes to investing in the Australian stock market, Exchange-Traded Funds (ETFs) are a popular choice. Two well-known options in the Australian Securities Exchange (ASX) are the Global X S&P Biotech ETF (CURE) and the Lanyon Investment Fund Active ETF (LNYN). In this comparison, we'll delve into these ETFs across various dimensions to help you make an informed investment decision.
Community Stats
CURE | LNYN | |
|---|---|---|
Popularity | Low | Low |
Pearlers invested | 82 | 1 |
Median incremental investment | $674.92 | $543.50 |
Median investment frequency | Monthly | Quarterly |
Median total investment | $2,318.70 | $571.35 |
Average age group | > 35 | 26 - 35 |
Key Summary
CURE | LNYN | |
|---|---|---|
Strategy | CURE.AX was created on 2018-11-08 by Global X. The fund's investment portfolio concentrates primarily on health care equity. The ETF currently has 46.59m in AUM and 158 holdings. The Fund aims to provide investors with a return that (before fees and expenses) tracks the performance of the S&P Biotechnology Select Industry Index. | LNYN.AX was created on 2019-09-02 by Lanyon. The fund's investment portfolio concentrates primarily on total market equity. The Funds investment return objective is to earn returns superior to the combined benchmark consisting of 75% of the S&P/ASX 300 Accumulation Index and 25% of the MSCI All Country World Index net total returns AUD index after taking account of fees and costs incurred by the Fund. |
Top 3 holdings | Moderna Inc (2.72 %) Exelixis Inc (1.80 %) Amgen Inc (1.79 %) | Mineral Resources Ltd (16.79 %) Telstra Group Ltd (14.42 %) Newmont Corp Chess Depository Interest (12.48 %) |
Top 3 industries | Health Care (100.00 %) Other (10.24 %) | |
Top 3 countries | United States (96.74 %) Switzerland (1.43 %) United Kingdom of Great Britain and Northern Ireland (1.23 %) | Australia (56.95 %) United States (18.38 %) United Kingdom of Great Britain and Northern Ireland (15.27 %) |
Management fee | 0.45 % | 0 % |
Key Summary
CURE | LNYN | |
|---|---|---|
Issuer | Global X | Lanyon |
Tracking index | S&P Biotechnology Select Industry | 75% S&P/ASX 300 Accumulation Index - AUD - Benchmark TR Net - 25% MSCI All Country World Index in AUD - AUD - Benchmark TR Net - NET_RETURN |
Asset class | ETF | ETF |
Management fee | 0.45 % | 0 % |
Price | $77.21 | $1.95 |
Size | $50.133 million | N/A |
10Y return | N/A | N/A |
Annual distribution yield (5Y) | 0.03 % | 1.97 % |
Market | ASX | ASX |
First listed date | 12/11/2018 | 31/07/2024 |
Purchase fee | $6.50 | $6.50 |
Community Stats
CURE | LNYN | |
|---|---|---|
Popularity | Low | Low |
Pearlers invested | 82 | 1 |
Median incremental investment | $674.92 | $543.50 |
Median investment frequency | Monthly | Quarterly |
Median total investment | $2,318.70 | $571.35 |
Average age group | > 35 | 26 - 35 |
Pros and Cons
CURE | LNYN | |
|---|---|---|
Pros |
|
|
Cons |
|
|
CURE | LNYN |
|---|---|
Lower exposure to AU market | Higher exposure to AU market |
Higher exposure to US market | Lower exposure to US market |
Higher management fee | Lower management fee |
Higher price growth | Lower price growth |
Lower distribution yield | Higher distribution yield |